medigraphic.com
ISSN 1527-3172 (Electronic)

2021, Number 2

<< Back Next >>

MEDICC Review 2021; 23 (2)

Using Multiple Cause-of-Death Analysis to Estimate Systemic Autoimmune Disease Mortality Burden in Low- and Middle-Income Countries

Hernández-Negrín H, Roque-Dapresa Y, Martínez-Morales O, Mederos-Portal A

Language: English
References: 54
Page: 69-74
PDF size: 148.40 Kb.


ABSTRACT

Autoimmune diseases are not always recognized as urgent health issues, despite a worldwide prevalence of 4%–5%. Most estimates come from high-income countries, as low- and middle-income countries face more issues of under-reporting. Despite this and the lack of recognition under current reporting practices, the role these diseases play in mortality must be acknowledged. In particular, considering multiple causes of death as opposed to a single cause of death results in a 1.5–4.2-fold increase in deaths classifi ed as relating to autoimmune diseases, evidence of their share in overall mortality burden, a factor important for patient care and healthcare policy decision making.
However, formulating such policies and programs for timely, appropriate diagnoses and care is stymied in low- and middle-income countries by the shortage of methodologically sound studies on mortality from systemic autoimmune diseases. This limitation exacerbates inequalities and health gaps among patients in different countries and localities.
Multiple cause-of-death methodology has been validated for research on other diseases and demonstrates the mortality burden of these illnesses in countries where traditional methodological approaches, primarily based on prospective cohort studies, are not feasible. Studying mortality from systemic autoimmune diseases by analyzing multiple causes of death with data from national mortality registries is a lowcost alternative to traditional mortality analysis. The objective of this paper is to demonstrate and defend the usefulness of this approach to estimate mortality burden.


REFERENCES

  1. Scherlinger M, Mertz P, Sagez F, Meyer A,Felten R, Chatelus E, et al. Worldwide trendsin all-cause mortality of auto-immune systemicdiseases between 2001 and 2014. AutoimmunRev [Internet]. 2020 Jun [cited 2020 Jul7];19(6):102531. Available at: http://dx.doi.org/10.1016/j.autrev.2020.102531

  2. Roberts MH, Erdei E. Comparative UnitedStates autoimmune disease rates for 2010-2016by sex, geographic region, and race. AutoimmunRev [Internet]. 2020 Jan [cited 2020 Jul7];19(1):102423. Available at: http://dx.doi.org/10.1016/j.autrev.2019.102423

  3. Thomas SL, Griffi ths C, Smeeth L, Rooney C,Hall AJ. Burden of mortality associated withautoimmune diseases among females in theUnited Kingdom. Am J Public Health. 2010Nov;100(11):2279–87.

  4. Cross M, Smith E, Hoy D, Carmona L, Wolfe F,Vos T, et al. The global burden of rheumatoidarthritis: estimates from the Global Burden ofDisease 2010 study. Ann Rheum Dis [Internet].2014 Jul [cited 2020 Jun 2];73(7):1316–22. Availableat: http://dx.doi.org/10.1136/annrheumdis-2013-204627

  5. Carter EE, Barr SG, Clarke AE. The globalburden of SLE: prevalence, health disparitiesand socioeconomic impact. Nat Rev Rheumatol[Internet]. 2016 Oct [cited 2020 Jun2];12(10):605–20. Available at: http://dx.doi.org/10.1038/nrrheum.2016.137

  6. Royle JG, Lanyon PC, Grainge MJ, Abhishek A,Pearce FA. The incidence, prevalence, and survivalof systemic sclerosis in the UK Clinical PracticeResearch Datalink. Clin Rheumatol [Internet]. 2018Aug [cited 2020 Jul 7];37(8):2103–11. Available at:http://dx.doi.org/10.1007/s10067-018-4182-3

  7. Meyer A, Meyer N, Schaeffer M, GottenbergJ-E, Geny B, Sibilia J. Incidence and prevalenceof infl ammatory myopathies: a systematicreview. Rheumatology. 2015 Jan [cited 2020 Jul7];54(1):50–63. Available at: http://dx.doi.org/10.1093/rheumatology/keu289

  8. Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, etal. Epidemiology of primary Sjogren’s syndrome:a systematic review and metaanalysis. AnnRheum Dis [Internet]. 2015 Nov [cited 2020 Jul7];74(11):1983–9. Available at: http://dx.doi.org/10.1136/annrheumdis-2014-205375

  9. Dey D, Sciascia S, Pons-Estel GJ, Ding H,Shen N. Health disparities in rheumatic diseases.Understanding global challenges in Africa,Europe, Latin America, and Asia and proposingstrategies for improvement. Rheum Dis Clin N Am[Internet]. 2021 [cited 2021 Feb 20];47(1):119–32. Available at: https://www.rheumatic.theclinics.com/article/S0889-857X(20)30121-6/pdf

  10. Reyes-Llerena GA, Guibert-Toledano M,Penedo-Coello A, Pérez-Rodríguez A, Baez-Dueñas RM, Charnicharo-Vidal R, et al. Community-based study to estimate prevalence andburden of illness of rheumatic diseases in Cuba:a COPCORD study. J Clin Rheumatol [Internet].2009 Mar [cited 2020 Jun 2];15(2):51–5.Available at: http://dx.doi.org/10.1097/RHU.0b013e31819b61cb

  11. Pincus T, Gibson KA, Block JA. Premature mortality:a neglected outcome in rheumatic diseases?Arthritis Care Res (Hoboken) [Internet]. 2015Aug [cited 2020 Jun 2];67(8):1043–6. Availableat: http://dx.doi.org/10.1002/acr.22554

  12. Abu-Shakra M, Novack V. Mortality and multiplecauses of death in systemic lupus erythematosus -Role of the death certifi cate. J Rheumatol [Internet].2012 Mar [cited 2020 Feb 5];39(3):458–60. Availableat: http://dx.doi.org/10.3899/jrheum.111556

  13. van Kruijsdijk RC, van der Graaf Y, Koffi jberg H,de Borst GJ, Nathoe HM, Jaap Kappelle L, et al.Cause-specifi c mortality and years of life lost inpatients with different manifestations of vasculardisease. Eur J Prev Cardiol [Internet]. 2016Jan [cited 2020 Jul 7];23(2):160–9. Available at:http://dx.doi.org/10.1177/2047487314566998

  14. Toledano E, Candelas G, Rosales Z, MartínezPrada C, León L, Abásolo L, et al. A meta-analysisof mortality in rheumatic diseases. ReumatolClin [Internet]. 2012 Nov–Dec [cited 2020 Jul7];8(6):334–41. Available at: http://dx.doi.org/10.1016/j.reuma.2012.05.006

  15. Cardiel MH, Ambriz Murillo Y. Epidemiología delas enfermedades infl amatorias reumatológicas.In: Alba Fériz R, Muñoz Louis R, Espinoza LR,Khamashta M, Matucci-Cerinic M, Sanmartí R,editors. Enfermedades Infl amatorias Reumatológicas.Bogotá: Producciones Científi cas Ltda;2016. Spanish.

  16. Woolf AD, Vos T, March L. How to measure theimpact of musculoskeletal conditions. Best PractRes Clin Rheumatol [Internet]. 2010 [cited 2020 Jun2];24(6):723–32. Available at: http://dx.doi.org/10.1016/j.berh.2010.11.002

  17. Falasinnu T, Rossides M, Chaichian Y, SimardJF. Do death certifi cates underestimate the burdenof rare diseases? The example of systemiclupus erythematosus mortality, Sweden, 2001-2013. Public Health Rep [Internet]. 2018 [cited2020 Jun 2];133(4):481–8. Available at: http://dx.doi.org/10.1177/0033354918777253

  18. Kiadaliri AA, Turkiewicz A, Englund M. Mortalityfrom musculoskeletal disorders includingrheumatoid arthritis in southern Sweden: Amultiple-cause-of-death analysis, 1998–2014. JRheumatol [Internet]. 2017 May [cited 2020 Jun2];44(5):571–9. Available at: http://dx.doi.org/10.3899/jrheum.161219

  19. Egidi V, Salvatore MA, Rivellini G, D’AngeloS. A network approach to studying cause-ofdeathinterrelations. Demogr Res [Internet]. 2018 Jan 26 [cited 2020 Jul 7];38(Art. 16):373–400. Available at: http://dx.doi.org/10.4054/DemRes.2018.38.16

  20. Santo AH, Souza JMP, Pinheiro CE, Souza DC,Sato EI. Trends in dermatomyositis- and polymyositisrelated mortality in the state of São Paulo,Brazil, 1985-2007: multiple cause-of-death analysis.BMC Public Health [Internet]. 2010 Oct 11[cited 2020 Jul 15];10:597. Available at: http://dx.doi.org/10.1186/1471-2458-10-597

  21. Sato EI, Souza DC, Santo AH. [Mortality profile related to systemic lupus erythematosus: amultiple cause-of-death analysis]. J Rheumatol[Internet]. 2012 [cited 2020 Jul 15];39(3):496–503. Available at: https://www.jrheum.org/content/39/3/496.long

  22. Yen EY, Singh RR. Brief report: Lupus-anunrecognized leading cause of death in youngfemales: a population-based study using nationwidedeath certifi cates, 2000-2015. ArthritisRheumatol [Internet]. 2018 Aug [cited 2020 Jul15];70(8):1251–5. Available at: http://dx.doi.org/10.1002/art.40512

  23. Elhai M, Meune C, Boubaya M, Avouac J,Hachulla E, Balbir-Gurman A, et al. Mapping andpredicting mortality from systemic sclerosis. AnnRheum Dis [Internet]. 2017 Nov [cited 2020 Jul17];76(11):1897–905. Available at: http://dx.doi.org/10.1136/annrheumdis-2017-211448

  24. Pinheiro FAG, Souza DCC, Sato EI. A study ofmultiple causes of death in rheumatoid arthritis.J Rheumatol [Internet]. 2015 Dec [cited 2020 Jul15];42(12):2221–8. Available at: http://dx.doi.org/10.3899/jrheum.150166

  25. Thomas G, Mancini J, Jourde-Chiche N, SarlonG, Amoura Z, Harlé JR, et al. Mortality associatedwith systemic lupus erythematosus in Franceassessed by multiple-cause-of-death analysis.Arthritis Rheumatol [Internet]. 2014 Sep [cited2020 Jul 15];66(9):2503–11. Available at: http://dx.doi.org/10.1002/art.38731

  26. Poubel Vieira de Rezende R, Altenburg GismondiR, Cesar Maleh H, de Miranda Coelho E, SartoriVieira C, Garcia Rosa M, et al. Distinct mortalityprofi le in systemic sclerosis: a death certifi catestudy in Rio de Janeiro, Brazil (2006–2015)using a multiple causes of death analysis. ClinRheumatol [Internet]. 2019 Jan [cited 2020 Jul15];38(1):189–94. Available at: http://dx.doi.org/10.1007/s10067-017-3951-8

  27. Hernández-Negrín H, Padilla-Cueto D, MartínezMorales O. Tendencia creciente en la mortalidadpor lupus eritematoso sistémico en América Latinacomo expresión de las desigualdades socialesen salud. [Increasing trend in mortality fromsystemic lupus erythematosus in Latin Americaas an expression of social disparities in health].Reumatol Clin [Internet]. 2020 Aug 10 [cited 2020Jul 7]. Available at: http://dx.doi.org/10.1016/j.reuma.2020.07.004. Spanish, English.

  28. Tazi Mezalek Z, Bono W. Challenges for lupusmanagement in emerging countries. Presse Med.2014 Jun [cited 2020 Jul 15];43(6 Pt 2):e209–e20. Available at: http://dx.doi.org/10.1016/j.lpm.2014.04.002

  29. Mesa Machado AC, Tejeiro Fernández A. Causasmúltiples de muerte. Rev Cub Hig Epidemiol[Internet]. 1998 Aug [cited 2020 Jun1];36(2):116–26. Available at: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1561-30031998000200004&lng=es&nrm=iso.Spanish.

  30. Seuc AH, Fernández L, Mirabal-Sosa M,González CA. Cuban application of two methodsfor analyzing multiple causes of death. MEDICCRev. 2018 Jul;20(3):30–5.

  31. Fernández González L, Seuc Jo AH, RodríguezGarcía CA. Método de mortalidad ponderadosegún múltiples causas de muerte. RevFinlay [Internet]. 2019 Oct [cited 2020 May29];9(3):197–209. Available at: http://www.revfinlay.sld.cu/index.php/finlay/article/view/701.Spanish.

  32. Mathers CD, Ma Fat D, Inoue M, Rao C, LópezAD. Counting the dead and what they died from:an assessment of the global status of causeof death data. Bull World Health Org. 2005Mar;83(3):171–7.

  33. National Health Statistics and Medical RecordsDivision (CU). 10 primeras causas de muertepor grupos de edad y sexo en el adulto mayor.Cuba 2008 [Internet]. Havana: Ministry of PublicHealth (CU); 2009 Aug [cited 2020 Dec 10]. 4 p.Available at: http://www.sld.cu/galerias/pdf/sitios/dne/adulto_mayor_10_1ras_causas_2008.pdf.Spanish.

  34. INFOMED [Internet]. Havana: Ministry of PublicHealth (CU); c1999–2021. Anuario Estadísticode Salud del Ministerio de Salud Pública; [cited2020 Dec 10]. Available at: http://www.bvscuba.sld.cu/2017/11/20/anuario-estadistico-de-salud-de-cuba/. Spanish.

  35. World Health Organization. International Classifi -cation of Diseases and related health problems,10th revision: Volume II. Geneva: World HealthOrganization; 1993.

  36. Estrategia en enfermedades reumáticas y musculoesqueléticasdel Sistema Nacional de Salud.Madrid: Ministerio de Sanidad, Servicios Socialese Igualdad; 2013. Spanish.

  37. Pérez Venegas JJ, Lama Herrera CM, SanzAmores R, Martínez Concepción E, AbadRamírez R, Aguiar García F, et al. Plan Andaluzde Enfermedades Reumáticasy y Musculoesqueléticas.Sevilla: Junta de Andalucía,Consejería de Salud; 2018. p. 79. Spanish.

  38. National Association of Chronic Disease Directors;Center for Disease Control and Prevention;Lupus Foundation of America. National PublicHealth Agenda for Lupus. A Blueprint for Action.Atlanta: Center for Disease Control and Prevention;2015. 31 p.

  39. Cardiel MH. Presente y futuro de las enfermedadesreumáticas en Iberoamérica. ¿Estamospreparados para hacerles frente? ReumatolClin [Internet]. 2011 Sep–Oct [cited 2020 Jul15];7(5):279–80. Available at: http://dx.doi.org/10.1016/j.reuma.2010.12.009. Spanish.

  40. Morales Ojeda R, Mas Bermejo P, Castell-FloritSerrate P, Arocha Mariño C, Valdivia Onega NC,Druyet Castillo D, et al. Transformaciones en elsistema de salud en Cuba y estrategias actualespara su consolidación y sostenibilidad. Rev PanamSalud Publica [Internet]. 2018 Apr [cited 2020Dec 10];42:e25. Available at: http://dx.doi.org/10.26633/RPSP.2018.25. Spanish, English.

  41. Corratgé Delgado H. Objetivos de Trabajo y Criteriosde Medidas para 2020. Ministerio de SaludPública. INFODIR [Internet]. 2020 [cited 2020Jun 1]:31. Available at: http://revinfodir.sld.cu/index.php/infodir/article/view/757. Spanish.

  42. Mitratza M, Klijs B, Hak AE, Kardaun JWPF,Kunst AE. Systemic autoimmune disease asa cause of death: mortality burden and comorbidities.Rheumatology (Oxford) [Internet]. 2021Mar 2 [cited 2020 Dec 10];60(3):1321–30. Availableat: http://dx.doi.org/10.1093/rheumatology/keaa537

  43. Benchimol EI, Smeeth L, Guttmann A, HarronK, Moher D, Petersen I, et al. The REporting ofstudies Conducted using Observational Routinely-collected health Data (RECORD) Statement.PLoS Med [Internet]. 2015 Oct 6 [cited 2020 Dec10];12(10):e1001885. Available at: http://dx.doi.org/10.1371/journal.pmed.1001885

  44. Venero Fernández SJ, Bonet Gorbea MH, LageDávila A, Macías Agraham C, Suárez Medina M.Mortalidad por inmunopatologías en Cuba, 1989-2003. Havana: National Hygiene, Epidemiology andMicrobiology Institute (CU); 2008 Jan. Spanish.

  45. Gomes T, Tadrous M, Mamdani MM, PatersonJM, Juurlink DN. The burden of opioid-relatedmortality in the United States. JAMA NetwOpen [Internet]. 2018 Jun 1 [cited 2020 Dec10];1(2):e180217. Available at: http://dx.doi.org/10.1001/jamanetworkopen.2018.0217

  46. Barbieri M, Désesquelles A, Egidi V, Demuru E,Frova L, Mesle F, et al. Obesity-related mortalityin France, Italy, and the United States: a comparisonusing multiple cause-of-death analysis. Int JPublic Health [Internet]. 2017 May 11 [cited 2020Dec 13];62(6):623–9. Available at: http://dx.doi.org/10.1007/s00038-017-0978-1

  47. Adair T, Lopez AD. The role of overweight andobesity in adverse cardiovascular diseasemortality trends: an analysis of multiple causeof death data from Australia and the USA.BMC Med [Internet]. 2020 Aug 4 [cited 2020Dec 13];18(1):199. Available at: http://dx.doi.org/10.1186/s12916-020-01666-y

  48. Santo AH, Puech-Leão P, Krutman M. Trends inaortic aneurysm- and dissection-related mortalityin the state of São Paulo, Brazil, 1985–2009: multiple-cause-of-death analysis. BMC Public Health[Internet]. 2012 Oct 10 [cited 2020 Dec 13];12:859.Available at: http://dx.doi.org/10.1186/14712458-12-859

  49. Barco S, Valerio C, Ageno W, Cohen AT, GoldhaberSZ, Hunt BJ, et al. Age-sex specifi c pulmonaryembolism-related mortality in the USA andCanada, 2000–18: an analysis of the WHO MortalityDatabase and of the CDC Multiple Causeof Death database. Lancet Respir Med [Internet].2020 Jan 1 [cited 2020 Dec 10];9(1):33–42.Available at: http://dx.doi.org/10.1016/S2213-2600(20)30417-3

  50. Pechholdová M. Sepsis-related mortality inthe Czech Republic: multiple causes of deathanalysis. Epidemiol Mikrobiol Imunol. 2017 Summer;66(2):73–9.

  51. Santo AH. Causes of death and mortality trendsrelated to hemophilia in Brazil, 1999 to 2016.Hematol Transfus Cell Ther [Internet]. 2020 Jun4 [cited 2020 Dec 13];S2531-1379(20)30056-0.Available at: http://dx.doi.org/10.1016/j.htct.2020.02.003

  52. Avouac J, Amrouche F, Meune C, Rey G, KahanA, Allanore Y. Mortality profi le of patients withrheumatoid arthritis in France and its changein 10 years. Semin Arthritis Rheum [Internet].2017 Apr [cited 2020 Dec 13];46(5):537–43.Available at: http://dx.doi.org/10.1016/j.semarthrit.2016.10.007

  53. Falasinnu T, Chaichian Y, Simard JF. Impact ofsex on systemic lupus erythematosus-relatedcauses of premature mortality in the UnitedStates. J Womens Health (Larchmt) [Internet].2017 Nov [cited 2020 Dec 13];26(11):1214–21. Available at: http://dx.doi.org/10.1089/jwh.2017.6334

  54. Souza DCC, Santo AH, Sato EI. Trends in systemiclupus erythematosus mortality rates in thestate of São Paulo, Brazil from 1985 to 2004. ClinExp Rheumatol. 2010 Jul–Aug;28(4):519–24.




2020     |     www.medigraphic.com